A detailed history of Fortitude Family Office, LLC transactions in Vaxcyte, Inc. stock. As of the latest transaction made, Fortitude Family Office, LLC holds 26 shares of PCVX stock, worth $2,302. This represents 0.0% of its overall portfolio holdings.

Number of Shares
26
Previous 26 -0.0%
Holding current value
$2,302
Previous $1.96 Million 51.35%
% of portfolio
0.0%
Previous 0.0%

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Jul 10, 2024

BUY
$60.06 - $78.77 $540 - $708
9 Added 52.94%
26 $1.96 Million
Q4 2023

Jan 12, 2024

BUY
$45.35 - $63.41 $770 - $1,077
17 New
17 $1.07 Million

Others Institutions Holding PCVX

About Vaxcyte, Inc.


  • Ticker PCVX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 59,315,100
  • Market Cap $5.25B
  • Description
  • Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in Phase 1/2 clinical trials to treat invasive pneumococcal disease and pneumonia. The company a...
More about PCVX
Track This Portfolio

Track Fortitude Family Office, LLC Portfolio

Follow Fortitude Family Office, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Fortitude Family Office, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Fortitude Family Office, LLC with notifications on news.